NCT04645199Recruiting
National Longitudinal Cohort of Hematological Diseases
National Longitudinal Cohort of Hematological Diseases (NICHE)
Source: ClinicalTrials.gov · Last updated 12 Feb 2026
Brief summary (registry, in English)
Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China. Method The study will include patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, large granular lymphocyte leukemia, essential thrombocythemia, blood infection or received bone marrow transplantation in the investigating hospitals from January 1, 2020, and collect basic information, diagnostic and treatment information, prognosis information, as well as medical expense information from medical records. In its current form, the NICHE registry incorporates historical data (collected from 2000) and is systematically collecting prospective data in two phases with broadening reach, and prospectively follow-up to collect the prognosis information.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2300 (estimated)
- First submitted
- 13 Nov 2020
- Start date
- 1 Dec 2020
- Primary completion date
- 1 Dec 2030
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Diseases
- Myeloproliferative neoplasms, Haemophilia, Myelodysplastic syndromes, Multiple myeloma, Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT04645199
What you commit to
- Study type: Observational
- Planned participants: 2300
- From 1 Dec 2020 to the primary completion date, 1 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
- Alcohol and drug addictions affect their ability to comply with study requirements.
Other illness
- According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.
Who the study is looking for
- Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Hematology & Blood Diseases Hospital Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
Related publications
- Patterns of clonal hematopoiesis in aplastic anemia under immunosuppressive therapy.Leukemia · 2026 · PMID 42693160
This page is information, not medical advice. Discuss any trial with your doctor.